ArticlePloS one2025
AKR1C2 silencing promotes ferroptosis and inhibits proliferation, migration, and invasion in lung cancer cells.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Landscape of Ferroptosis-Related Gene Signatures as Molecular Stratification in Triple-Negative Breast Cancer.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is the leading cause of cancer-related deaths worldwide, so research and development of potential therapeutic targets is urgent.
methodsThe target gene, AKR1C2, was screened using the TCGA and FerrDb databases. The expression of AKR1C2 in lung cancer, its correlation with the clinical characteristics of patients, and the biological roles and molecular mechanisms involved were assessed by bioinformatics. The expression levels of AKR1C2 in normal lung epithelial cells and lung cancer cells were compared by qRT-PCR and Western blot. The effects of AKR1C2 knockdown on the malignant phenotype of lung cancer cells were evaluated using Transwell, wound healing, and CCK8 assays. Finally, the impact of silencing AKR1C2 on malondialdehyde, reactive oxygen species, Fe2+ levels, and ferroptosis-related genes in lung cancer cells were experimentally investigated.
resultsAKR1C2 is highly expressed in lung adenocarcinoma tissues, and the expression level correlates with patient gender, tumor stage, lymph node metastasis, and prognosis. AKR1C2 is associated with substance metabolism, steroid hormone biosynthesis, cellular lipid metabolism, and oxidoreductase activity. AKR1C2 had high expression levels in A549 cells. AKR1C2 silencing inhibited cell viability, invasion, and migration. In A549 cells, AKR1C2 knockdown markedly raised the levels of reactive oxygen species, malondialdehyde, and Fe²⁺. The knockdown of AKR1C2 regulated the expression of ferroptosis-related genes.
conclusionOur study demonstrates that AKR1C2 knockdown promotes ferroptosis and inhibits malignant biological behaviors in lung cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.